455 related articles for article (PubMed ID: 30412003)
1. Systemic treatments for metastatic urothelial carcinoma.
Lalani AA; Sonpavde GP
Expert Opin Pharmacother; 2019 Feb; 20(2):201-208. PubMed ID: 30412003
[TBL] [Abstract][Full Text] [Related]
2. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
[TBL] [Abstract][Full Text] [Related]
3. Emerging drugs for urothelial (bladder) cancer.
Cumberbatch K; He T; Thorogood Z; Gartrell BA
Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
[TBL] [Abstract][Full Text] [Related]
4. Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline.
Jamy O; Sonpavde G
Expert Opin Emerg Drugs; 2017 Dec; 22(4):347-355. PubMed ID: 29226734
[TBL] [Abstract][Full Text] [Related]
5. The emerging treatment landscape of advanced urothelial carcinoma.
Cardenas L; Dibajnia P; Lalani AK
Curr Opin Support Palliat Care; 2021 Dec; 15(4):247-252. PubMed ID: 34620772
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward.
Bilé-Silva A; Lopez-Beltran A; Blanca A; Lopez-Rios F; Gómez-Gómez E; Cimadamore A; Montironi R; Vau N; Cheng L
Expert Opin Biol Ther; 2023 May; 23(5):407-418. PubMed ID: 37036223
[TBL] [Abstract][Full Text] [Related]
7. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.
Stühler V; Maas JM; Bochem J; da Costa IA; Todenhöfer T; Stenzl A; Bedke J
World J Urol; 2019 Sep; 37(9):1773-1784. PubMed ID: 30374610
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.
Aragon-Ching JB; Trump DL
Future Oncol; 2016 Sep; 12(17):2049-58. PubMed ID: 27306417
[TBL] [Abstract][Full Text] [Related]
9. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
Einstein DJ; Sonpavde G
Curr Treat Options Oncol; 2019 Feb; 20(2):12. PubMed ID: 30741358
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab in invasive and metastatic urothelial carcinoma.
Crist M; Balar A
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1295-1301. PubMed ID: 28994323
[TBL] [Abstract][Full Text] [Related]
11. Erdafitinib for the treatment of metastatic bladder cancer.
Montazeri K; Bellmunt J
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
[No Abstract] [Full Text] [Related]
12. Advances in the management of urothelial carcinoma: is immunotherapy the answer?
Santopietro AL; Einstein D; Bellmunt J
Expert Opin Pharmacother; 2021 Sep; 22(13):1743-1759. PubMed ID: 33905290
[No Abstract] [Full Text] [Related]
13. Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need.
Montazeri K; Sonpavde G
Expert Rev Anticancer Ther; 2021 Mar; 21(3):299-313. PubMed ID: 33249937
[TBL] [Abstract][Full Text] [Related]
14. Avelumab for the treatment of urothelial cancer.
Rodriguez-Vida A; Bellmunt J
Expert Rev Anticancer Ther; 2018 May; 18(5):421-429. PubMed ID: 29540084
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
16. Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma.
Tang Q; Li S; Huang G; Liu H
Int Immunopharmacol; 2023 Jun; 119():110158. PubMed ID: 37062259
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel for the treatment of bladder cancer.
Albany C; Sonpavde G
Expert Opin Investig Drugs; 2015; 24(12):1657-64. PubMed ID: 26535615
[TBL] [Abstract][Full Text] [Related]
18. Durvalumab for the treatment of urothelial carcinoma.
Alsharedi M; Srivastava R; Elmsherghi N
Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in the treatment of advanced bladder cancer.
Godwin JL; Hoffman-Censits J; Plimack E
Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab in urothelial cancers.
Lavaud P; Hamilou Z; Loriot Y; Massard C
Expert Rev Anticancer Ther; 2018 Apr; 18(4):311-318. PubMed ID: 29486607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]